awmsg logo



eculizumab (Soliris®)


Reference No. 2007

Publication date:
03/12/2013


Appraisal information

eculizumab (Soliris®) 300 mg concentrate for solution for infusion


Company: Alexion Pharma UK Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, eculizumab (Soliris®) cannot be endorsed for use within NHS Wales in children for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS).
Statement of Advice (SOA)
Download